We have shown that the novel pNaKtide has been able to mitigate both dyslipidemia and atherosclerosis through attenuation of c-Src and ERK1/2 signaling, which is corroborated with improved plasma ROS and TBARS levels. This evidence concerns the gene SRC and atherosclerosis.